ABMD News and Press, ABIOMED Inc. From 08/18/21

The United States Food and Drug Administration (FDA) has granted breakthrough device designation to Abiomed ’s (NASDAQ: ABMD) Impella ECP expandable percutaneous heart pump. The designation means the FDA will prioritize Impella ECP’s regulatory review processes inc...

Abiomed, Inc. (ABMD) Q1 2022 Earnings Conference Call August 05, 2021 08:00 AM ET Company Participants Todd Trapp - Vice President and Chief Financial Officer Mike Minogue - Chairman, President and Chief Executive Officer Conference Call Participants Margaret Kaczor - William Blair & Comp...

Image source: The Motley Fool. ABIOMED, inc (NASDAQ: ABMD) Q1 2022 Earnings Call Aug 5, 2021 , 8:00 a.m. ET Operator Continue reading For further details see: ABIOMED, inc (ABMD) Q1 2022 Earnings Call Transcript

Abiomed (NASDAQ:ABMD) shares rise nearly 6% premarket on the back of reporting first-quarter revenue that beat Wall Street estimates and raised its financial forecast for the year. The company hiked its FY 2022 global revenue forecast to $1,030M - $1,050M from $990M to $1,030M vs. c...

The following slide deck was published by Abiomed, Inc. in conjunction with their 2022 Q1 earnings call. For further details see: Abiomed, Inc. 2022 Q1 - Results - Earnings Call Presentation

­ Full year global revenue guidance increased for fiscal year 2022 to 22% - 24% growth versus prior year Abiomed, Inc. (NASDAQ: ABMD), a leading provider of breakthrough heart support technologies, today announced financial results for the quarter ended ...

Abiomed, Inc . (NASDAQ: ABMD) announced that on Thursday, August 5, 2021, the Company will release financial results for the first quarter of the fiscal year 2022. The Company will host a conference call to discuss the results on Thursday, August 5, 2021 at 8:00 a.m. ET. Michael R. ...

Abiomed has commenced its path to recovery on the charts, following a big hit in April this year. Key tension points for ABMD's share price lie in its Impella sales volume, which continues to gain traction sequentially as we walk through this year. Shares are trading at a premium ...

jayk7/Moment via Getty Images Abiomed (ABMD) announced that the FDA issued the pre-market approval ((PMA)) for the right heart pump, the Impella RP with SmartAssist as a potential treatment of acute right heart failure for up to 14 days. “Impella RP with SmartAssist further improv...

Abiomed’s (NASDAQ: ABMD) newest right heart pump, the Impella RP with SmartAssist, has received U.S. Food and Drug Administration (FDA) pre-market approval (PMA) as safe and effective to treat acute right heart failure for up to 14 days. This press release features multim...